Paul Bananos
Director of Biopharma Intelligence and industry analyst who provides coverage of biotech deals, funds, and M&A activity including Gilead's and Neurocrine's transactions.
Best podcasts with Paul Bananos
Ranked by the Snipd community
11 snips
Apr 14, 2026 • 34min
Ep. 360 - FDA’s FIH plans. Plus: billion-dollar deals, funds
Paul Bananos, biopharma analyst tracking big biotech deals and funds. Simone Fishburne, industry editor covering translational science and regional regulatory trends. Steve Usdin, Washington editor focused on FDA policy and first-in-human rules. They debate FDA’s bold plan to shorten preclinical pathways, compare approaches in Australia, China and the U.K., and unpack recent billion-dollar acquisitions and huge new life‑science funds.
